VytronUS, Inc. was formed to harness the imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. The company has developed a catheter-based ablation platform employing Low-Intensity Collimated Ultrasound (LICU™). LICU allows for non-contact energy delivery and is capable of quickly producing high-resolution images of cardiac anatomy. The VytronUS system is designed to allow physicians to easily treat complex arrhythmias with better flexibility and control.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/29/14 | $31,600,000 | Series B |
Apple Tree Partners BioStar Ventures Windham Venture Partners | undisclosed |
| 07/29/16 | $49,000,000 | Series C |
Apple Tree Partners BioStar Ventures Windham Venture Partners | undisclosed |
